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Treatment of  mycotic aortic aneurysm by excision and extraanatomic bypass is difficult to 
apply when the infectious process involves the visceral arteries. On the basis of  
experimental studies in our laboratory that demonstrated prolonged antistaphylococcal 
activity of rifampin-bonded, gelatin-impregnated Dacron grafts after implantation in the 
arterial circulation, this conduit was successfully used for in situ replacement of  a native 
aortic infection in two patients. Both patients had fever, leukocytosis, abdominal or back 
pain, and a computed tomographic scan that demonstrated contained rupture of  a mycotic 
aneurysm. Preoperative computed tomography-guided aspiration and culture ofperiaor- 
tic fluid from one patient grew Staphylococcus aureus.  Treatment consisted of prolonged (6 
weeks) culture-specific parenteral antibiotic therapy, excision of  involved aorta, oxychlo- 
rosene irrigation of the aortic bed, and restoration of  aortic continuity by in situ prosthetic 
replacement. A preliminary right axillobifemoral bypass was performed in the patient who 
had an infection involving the suprarenal and infrarenal aorta. In both patients 
intraoperative culture of  aorta wall recovered S. aureus.  Patients were discharged at 20 and 
21 days. Clinical follow-up and computed tomographic imaging of  the replacement graft 
beyond 10 months after surgery demonstrated no signs of residual aortic infection. In the 
absence of  gross pus and frank sepsis, the use of an antibiotic-bonded prosthetic graft with 
antistaphylococcal ctivity should be considered in patients who have arterial infections 
caused by S. aureus  when excision and ex situ bypass are not feasible. (J Vase Surg 
1996;24:472-6.) 
Treatment of mycotic abdominal aortic aneu- 
rysm (AAA) remains one of the most challenging 
clinical problems vascular surgeons encounter. The 
incidence, although low (1% to 3 % of all AAAs) 
appears to be increasing, a'2 Standard treatment 
involves excision of the infected aorta, aggressive 
surgical debridement of pcriaortic tissue, closure of 
the aortic stump, and reestablishment of distal ar- 
terial flow through extraanatomic routes. Life- 
time culture-specific administration of antibiotics is 
usually recommended. Despite appropriate and 
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timely surgical intervention, reported mortality and 
morbidity rates remain high (>70%). 3 In situ re- 
placement of the infected aorta after removal of 
grossly infected or inflamed tissue has also been 
performed, but death as a result of persistent in- 
fection has been reported in as many as 80% 
of patients. 4,s The use of antibiotic-bonded grafts 
is an attractive surgical adjunct for the treatment 
of mycotic AAA when in situ replacement is 
deemed feasible. This reasoning is based on animal 
and human studies that demonstrated improved 
results when rifampin-bonded Dacron grafts were 
used as in situ replacements for infected aortic 
grafts. 6-1° On the basis of these clinical and ex- 
perimental data, we used rifampin-bondcd grafts for 
in situ replacement of the aorta in two patients who 
had ruptured mycotic aneurysms. This report details 
the preliminary results of the use of  a rifampin- 
bonded gelatin-impregnated Dacron graft for treat- 
ment of mycotic AAA caused by Staphylococcus 
a~'gUs. 
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Fig. 1. Case 1. Abdominal CT scan shows drainage attempt of psoas abscess, which later was 
diagnosed as mycotic abdominal aortic aneurysm at suprarenal level (arrow). 
Fig. 2. Case 1. Lateral abdominal aortogram shows posteriorly directed aortic aneurysm. 
CASE REPORTS 
Case 1. A 77-year-old woman was admitted to an 
outlying hospital with severe lower back and abdominal 
pain, night sweats, and a leukocytosis (20,000/mm3). A 
computed tomographic (CT) scan of the abdomen revealed 
a retroperitoneal fluid collection that was believed to be a 
psoas abscess. Needle aspiration grew S. aureus (Fig. 1). 
After 10 days ofinra~avenous antibiotics an arteriogram was 
ordered, which revealed a mycotic suprarenal AAA. After 
transfer to our hospital, an initial right axillofemoral bypass 
was followed by left retroperitoneal thoracoabdominal 
exposure of the aorta. The mycotic aneurysm was opened, 
disclosing a rupture posteriorly (Fig. 2). Gram stain re- 
vealed gram-positive cocci n pairs. The aneurysm extended 
posteriorly from the level of the celiac axis to the left renal 
artery (Fig. 3). The aortic wall and surrounding tissues were 
debrided and retroperitoneal irrigation was performed with 
Clorpactin solution (Guardian Laboratories, Hauppauge, 
N.Y.; 3 g Clorpactin mixed with 1 L saline solution) using 
a wound irrigation system (Stryker SurgiLav Plused irriga- 
tion system with handpiece and high-flow trauma tip, 
Kalamazoo, Mich.). The rifampin graft was produced by 
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Fig. 3. Case 1. Anterolateral view of abdominal aorta 
depicts location and extent of mycotic aneurysm. 
soaking at room temperature in a 60 mg/ml  solution (1200 
mg Rifadin rifampin powder in 20 ml sterile saline solution, 
Merrill Dow Pharmaceutical, Kansas City, Mo.) for 15 
minutes. This 20-ram gelatin-impregnated (Gelseal, Vas- 
cutek Ltd., Glasgow, United Fdngdom) Dacron graft was 
spatulated onto the origin of the great vessels anteriorly and 
carried down distally to just above the level of the inferior 
mesenteric artery (Fig. 4). The patient continued to receive 
intravenous antibiotics for 6 weeks, followed by oral anti- 
biotics for 2 months. ACT  scan and clinical evaluation at 1[l 
months revealed an intact anastomosis and no sign of 
recurrent infection. The axillofemoral graft has remained 
patent. 
Case 2. A 73-year-old man who previously had had a 
4-cm AAA sought medical attention for a 5-day history of 
increasing abdominal pain. A CT scan demonstrated a 
5.2-cm AAA with periaortic fluid (Fig. 5). The patient was 
hemodynamically stable, had a low-grade fever, and a 
leukocytosis of 18,000 mm 3. After parcnteral antibiotics 
were administered, surgical exploration was performed 
through a left retroperitoneal incision. An infected infrare- 
Fig. 4. Case 1. Completed in situ reconstruction with 
rifampin-impregnated Dacron Gelseal graft spatulated onto 
origins of great vessels. 
hal aortic aneurysm with a contained posterior rupture was 
evident on the right side. Gram stain demonstrated gram- 
positive cocci in pairs. Because the aneurysm extended to 
the level of the renal arteries, precluding infrarenal aortic 
stump closure, an in situ interposition grafting procedure 
was performed with a rifampin-bonded graft. Aneurysm 
wall and adjacent involved retroperitoneal tissues were 
debrided. A systec Clorpactin irrigation system was used to 
deliver 2 L of solution to the retropetitoneal tissues. The 
patients' intraoperative tissue cultures grew S. aureus, and 
parenteral ntibiotics were administered for 6 weeks after 
surgery. Oral antibiotics were administered for an additional 
2 months and had to be discontinued because of gas- 
trointestinal intolerance, Follow-up evaluation and a CT 
scan at 10 months revealed no signs of recurrent infection. 
DISCUSSION 
The involvement o f  the abdominal  aorta with 
infection constitutes 22% of  all mycotic aneurysms, 
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Fig. 5. Case 2. Abdominal CT scan shows infrarenal aortic aneurysm with probable periaortic 
fluid. 
and is second only tothe femoral artery in frequency. 2 
In 1885 Sir William Osier used the term "mycotic" to 
describe arterial infections resulting from bacterial 
endocarditis. 1 Salmonellae and S. aureus continue to 
be the most prevalent organisms isolated. 2 An in- 
creased incidence of infected aneurysms have also 
been seen as a result of greater use of invasive 
monitoring, drug addition, and the prevalence of 
aging and immunosuppressed hosts. 
Mycotic AAAs are fatal without surgical t/eat- 
ment. Operative techniques have varied from excision 
and in situ graft replacement to resection and ex situ 
(axillobifemoral) bypass. Cases have been reported of 
infected aneurysms uccessfully being treated with 
non-antibiotic-impregnated in situ and in-line retro- 
peritoneal polytetrafluoroethylene grafts, but most 
studies continue to demonstrate high recurrent infec- 
tion and mortality rates. 12aa Walker et al. s cite a 43% 
complication rate and a 22% mortality rate in patients 
who have aortic infections treated with debridement 
and in situ prosthetic graft placement. 5 Fichelle et al.1 
report septic aortic complication rates as high as 22%. 
Standard surgical treatment of preliminary ex- 
traanatomic (axillobifemoral) bypass for preservation 
of the leg and gluteal perfusion combined with aortic 
graft excision has several drawbacks, including aortic 
stump blowout (20%). In addition, lower axillofemo- 
ral graft patency rates with increased rates of ampu- 
tation (50%), reinfection (15% to 40%), and gluteal 
ischemia are also reported. 14q7 Naylor et al. 18 re- 
ported a 50% mortality rate within 30 days and a 25% 
major-limb amputation rate in their patients who 
were treated in this manner. Reddy et a1.19 managed a 
mycotic AAA of a type similar to that in the patient in 
Case 1 without using in situ graft replacement. The 
infected aorta was resected and suprarenal closure 
performed to maintain patency of the superior mes- 
enteric and celiac arteries. Reimplantation of the left 
kidney to the left iliac artery and an axillofemoral 
bypass then was performed. Unfortunately, the axil- 
lofemoral graft thrombosed, and a retroperitoneal 
thoracoiliac graft was constructed; the patient died of 
a myocardial infarction 2 weeks later. There are 
circumstances in which the use of axillofemoral or 
thoracoabdominal bypasses are not possible and in 
which in situ bypasses must be performed, as in 
patients who have infected supraceliac or renal aortic 
aneurysms. Atnip 3 reviewed 18 patients who had 
infected suprarenal AAAs and found an 88% long- 
term survival rate, although he did report a 100% 
mortality rate in patients who had ruptured mycotic 
AAAs who were treated in a similar manner. 
Both of our patients had a contained rupture of a 
mycotic AAA and survived in situ graft replacement. 
The use ofa rifampin-bonded graft may have contrib- 
uted to the successful control of periaortic infection. 
This approach was selected because gram-positive 
organisms were involved and there was no extensive 
retroperitoneal infection. In addition, the use of 
Clorpactin irrigation during surgery and long-term 
antibiotic administration may have contributed to 
decreasing reinfection. Rifampin has a broad spec- 
trum of antibacterial ctivity and is bactericidal to 
staphylococcal organisms, especially S. aureus, at low 
serum concentrations. Reports have been published 
of other antibiotics uch as vancomycin, oxacillin, 
penicillin, and amikacin used in a similar manner, but 
none have comparable affinity to binding graft mate- 
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rial, low toxicity, and antibacterial activity exhibited 
by rifampin. 2° We demonstrated, in an animal model, 
bactericidal staphylococcal ctivity on graft surfaces 
for at least 2 days after aortic replacement. 9 Rifampin 
bonding is both active and passive in nature, forming 
ionic bonds between the N-4 methyl piperazine 
group ofr i fampin and the carboxyl groups of  gelatin 
with succinyl. This leads to a high affinity ofr i fampin 
for the gelatin-coated knitted Dacron graft)  x Bond- 
ing ofrifampin to Dacron vascular prostheses has not 
been associated with increased thrombogenicity 
when used for aortic replacement, and the emergence 
of  rifampin-resistant strains have not been re- 
ported. 3.8,22,23 
The use of  a rifampin-impregnated Gelseal Da- 
cron graft as an in-situ replacement graft should be 
considered when gram-positive organisms are present 
and there are no signs of  frank purulence. Infection 
rates, as well as mortality and morbidity rates, are 
much lower for rifampin-treated grafts than for plain 
in situ graft replacement. 6~8 The three postulates that  
dictate effective treatment of infccted AAAs continue 
to bc: (1) debridcment of  infected or necrotic retro- 
peritoneal tissue; (2) establishment o f  adequate pe- 
ripheral perfusion; and (3) prevention of  aortic rein- 
fection with antibiotic agents. The ultimate choice 
depends on factors such as patient health, comorbid 
factors, suspected aortic organisms, extent ofperiaor- 
tic infection, ease of  dissection, and level o f  aortic 
involvement (abscess). Rifampin-impregnated grafts 
are being used clinically in patients with gram-positive 
vascular infections, supraccliac aortic involvement, 
and low-grade recurrent aortoiliofemoral graft infec- 
tions. 6-8'18'21 Although they are still in the early clinical 
trial period, we believe that rifampin-impregnated 
grafts are a useful adjacent in the treatment o f  mycotic 
aneurysms caused by S. aureus. 
REFERENCES 
1. Fichelle IM, Tabet G, Cormier P, Farkas JC, Laurian C, Gigou 
F, et al. Infected infrarenal ortic aneurysms: when is in situ 
reconstruction safe? J Vasc Surg 1993;17:635-45. 
2. Bandyk DF. Vascular infections. In: Greenfield LJ, editor. 
Surgery: scientific principles and practice. 1st ed. Philadelphia: 
JB Lippincott, 1993:1568-79. 
3. Atnip RG. Mycotic aneurysms of the suprarenal bdominal 
aorta: prolonged survival after in situ aortic and visceral 
reconstruction. J Vasc Surg 1989;10:635-41. 
4. Jacobs MIHM, Reul GJ, Gregoric I, Coley DA. In-sitn 
replacement and extra-anatomic bypass for the treatment of 
infected abdominal ortic grafts. Enr J Vasc Surg 1991;5:83-6. 
5. Walker WE, Cooley DA, Duncan JM, Hallman GL, Ott DA, 
Reul GJ. The management of aortoduodenal fistula by in-situ 
replacement of the infected abdominal ortic graft. Ann Surg 
1987;205:727-32. 
6. Colburn MD, Moore WS, Chvapil M, Gelabert HA, Qui- 
fiones-Baldrich WI. Use of an antibiotic-bonded graft for in 
situ reconstruction after prosthetic graft infections. J Yasc Surg 
1992;16:651-60. 
7. Goeau-Brissonniere O, Mercier F, Nicolas MH, Bacourt F, 
Coggia M, Lebrault C, Pechere. Treatment of vascular graft 
infection by in situ replacement with a rifampin-bonded 
gelatin-sealed Dacron graft. J Vasc Surg 1994;19:739-44. 
8. Lachapelle K, Graham AM, Symes IF. Antibacterial ctivity, 
antibiotic retention, and infection resistance of a rifampin- 
impregnated gelatin-sealed Dacron graft. J Vase Surg 1994; 
19:675-82. 
9. Gahtan V, Esses GE, Bandyk DF, Nelson RT, Dupont E, Mills 
JL. Antistaphylococcal activity of rifampin-bonded gelatin- 
impregnated Dacron grafts. J Surg Res 1995;58:105-10. 
10. Freyier A, Curti T, Rodio M, Masetti L, Bignozzi L, San- 
guinetti V, ctal. Interaction between vascular prostheses and 
rifampin in the prevention of graft infections: an experimental 
study. Int Angiol 1992;11:113-6. 
11. Osier W. The Gulstonian lectures on malignant endocarditis. 
BMJ 1885;1:467. 
12. Leather RP, Darling RC, Chang BB, Shah DM. Retroperito- 
heal in-line aortic bypass for treatment of infected infrarenal 
aortic grafts. Surg Gynecol Obstet 1992;175:491-4. 
13, Hollier LH, Money SR, Creely B, Bower TC, Kazmier FJ. 
Direct replacement of mycotic thoracoabdominal aneurysms. 
J Vase Surg 1993;18:477-85. 
14. Naylor AR, Engeset J, Ah-See AK. Prosthetic graft infection 
after aortofemoral grafting for peripheral limb ischemia. J R 
Coil Surg Edinb 1988;33:31-4. 
15. Goldstone J. The infected infrarenal aortic graft. Acta Chir 
Scand 1987;538:72-86. 
16. Roy A, Hayes DF. Closure of an aortic stump. Am J Surg 
1983;145:I262-76. 
17. O'Btien T, Collin J. Prosthetic vascular graft infection. Br J 
Surg 1992;79:1262-7. 
18. Naylor AR, Clark S, London NJM, Sayers RD, Macpherson 
DS, Barrie WW, Bell PRF. Treatment of major aortic graft 
infection: preliminary experience with total graft excision and 
in situ replacement with a rifampin-bonded prosthesis. Eur J 
Vase Endovasc Surg 1995;9:252-6. 
19. Reddy DJ, Lee RE, Oh HI(. Suprarenal mycotic aortic 
aneurysm: surgical management and follow-up. J Vase Surg 
1986;3:917-20. 
20. Magnan PE, Seyral P, Raoult D, Branchereau A. In vitro 
antistaphylococcal activity of collagen-sealed Dacron vascular 
prostheses bonded with rifampin, vancomycin, or amikacin. 
Ann Vase Surg 1994;8:243-7. 
21. D'Addato M, Curti T, Frcyrie GB, Bertini D, Biasi G. 
Prevention of early graft infection with rifampin-bonded 
Gdseal grafts: a multicentre experimental study. Cardiovasc 
Surg 1994;2:254-8. 
22. Sardellc F, Ao P¥, Fletcher JP. Rifampin-imprcgnated Dacron 
grafts: no developlncnt of rifampin resistance in an animal 
model. Eur J Vase Endovasc Surg 1995;9:314-8. 
23. Lundell A, Bergqvist D, Lindblad B, Leide S. The acute 
thrombogenicity of an infection-resistant rifampin-soal<ed Da-
cron graft: an experimental study in sheep. Eur J Vasc Surg 
1992;6:403-7. 
Submitted Jan. 31, 1996; accepted Apr. 12, 1996. 
